ALX Oncology SVP granted 192,000 stock options

Q: What insider transaction did ALXO report for Shelly Pinto?

ALX Oncology reported that SVP, Finance and CAO Shelly Pinto received a grant of 192,000 stock options on January 26, 2026. The options relate to common stock and are held directly as a derivative security position.

Q: What is the exercise price of Shelly Pinto’s ALXO stock options?

The granted stock options have an exercise price of $1.48 per share. This means Pinto can buy ALX Oncology common stock at $1.48 once the options vest and are exercisable, regardless of the market price at that time.

Q: How many ALXO options does Shelly Pinto hold after this transaction?

Following this transaction, Shelly Pinto beneficially owns 192,000 stock options in ALX Oncology. All of these options come from the January 26, 2026 award and are reported as direct ownership on the insider filing.

Q: How do Shelly Pinto’s ALXO stock options vest over time?

The stock options granted to Shelly Pinto vest in 48 equal monthly installments, starting on February 26, 2026. Each month, one forty-eighth of the total options becomes exercisable, gradually increasing her ability to purchase common shares.

Q: When do Shelly Pinto’s ALXO stock options expire?

The reported stock options are scheduled to expire on January 25, 2036. After this expiration date, any unexercised options will lapse, so they must be exercised before that date to convert into ALX Oncology common stock.

ALX Oncology Holdings Inc. officer Shelly Pinto was granted 192,000 stock options on January 26, 2026.

Accepted by SEC EDGAR 01/28/2026 - 04:30 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

ALX Oncology Holdings Inc. officer Shelly Pinto was granted 192,000 stock options on January 26, 2026. These options have an exercise price of $1.48 per share and were awarded at a cost of $0.00 to Pinto.

The options relate to ALX Oncology common stock and are held directly. They become exercisable over time, vesting in 48 equal monthly installments beginning on February 26, 2026, and are scheduled to expire on January 25, 2036 if not exercised.

Insider Trade Summary

Grant/Award: 192,000 shares

Grant/Award 1 txn

Insider Pinto Shelly

Role SVP, FINANCE AND CAO

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	192,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 192,000 contracts (Direct)

Footnotes (1)

F1. Shares subject to the option vest in 48 equal monthly installments beginning on February 26, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ALXO report for Shelly Pinto?

ALX Oncology reported that SVP, Finance and CAO Shelly Pinto received a grant of 192,000 stock options on January 26, 2026. The options relate to common stock and are held directly as a derivative security position.

What is the exercise price of Shelly Pinto’s ALXO stock options?

The granted stock options have an exercise price of $1.48 per share. This means Pinto can buy ALX Oncology common stock at $1.48 once the options vest and are exercisable, regardless of the market price at that time.

How many ALXO options does Shelly Pinto hold after this transaction?

Following this transaction, Shelly Pinto beneficially owns 192,000 stock options in ALX Oncology. All of these options come from the January 26, 2026 award and are reported as direct ownership on the insider filing.

How do Shelly Pinto’s ALXO stock options vest over time?

The stock options granted to Shelly Pinto vest in 48 equal monthly installments, starting on February 26, 2026. Each month, one forty-eighth of the total options becomes exercisable, gradually increasing her ability to purchase common shares.

When do Shelly Pinto’s ALXO stock options expire?

The reported stock options are scheduled to expire on January 25, 2036. After this expiration date, any unexercised options will lapse, so they must be exercised before that date to convert into ALX Oncology common stock.

Did Shelly Pinto pay anything to receive these ALXO stock options?

According to the insider report, the options were granted at a price of $0.00 per option. Pinto would only pay the $1.48 exercise price per share if and when she chooses to exercise vested options to acquire common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pinto Shelly

(Last)

(First)

(Middle)

C/O ALX ONCOLOGY HOLDINGS INC.

323 ALLERTON AVENUE

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ALX ONCOLOGY HOLDINGS INC [ ALXO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, FINANCE AND CAO

3. Date of Earliest Transaction (Month/Day/Year)
01/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock option (right to buy)	$1.48	01/26/2026		A		192,000		⁽¹⁾	01/25/2036	Common Stock	192,000	$0	192,000	D

Explanation of Responses:

1. Shares subject to the option vest in 48 equal monthly installments beginning on February 26, 2026.

	/s/ Shelly Pinto	01/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR